Showing results (41-50 of 50) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Medicinal Chemistry|May 10, 2007
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activitySrinivas R Kasibhatla, Kevin Hong, Marco A Biamonte, et al.Journal of Medicinal Chemistry|January 20, 2006
Orally active purine-based inhibitors of the heat shock protein 90Marco A Biamonte, Jiandong Shi, Kevin Hong, et al.Journal of Cannabis Research|February 2, 2021
A single nucleotide polymorphism assay sheds light on the extent and distribution of genetic diversity, population structure and functional basis of key traits in cultivated north American cannabisPhilippe Henry, Surender Khatodia, Karan Kapoor, et al.Journal of Medicinal Chemistry|August 18, 2006
7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitorsLin Zhang, Junhua Fan, Khang Vu, et al.Frontiers in Oncology|December 19, 2023
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survivalRao Prabhala, William E Pierceall, Mehmet Samur, et al.Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.Haematologica|August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasoneMeletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.Bioorganic & Medicinal Chemistry Letters|July 30, 2011
Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I)Lin Zhang, Junhua Fan, Jer-Hong Chong, et al.Journal of Medicinal Chemistry|September 4, 2012
EC144 is a potent inhibitor of the heat shock protein 90Jiandong Shi, Ryan Van de Water, Kevin Hong, et al.Pageof 5